Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN versus INNOHEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN versus INNOHEP.
Enoxaparin vs INNOHEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
Subcutaneous administration: 2500 IU anti-Xa (0.25 mL) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 mL) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin